Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
Related Questions
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
What are your top takeaways in GU Cancers from ESMO 2024?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
How do you manage anemia associated with belzutifan therapy?
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
What are your top takeaways from ASCO GU 2025?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
